News

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.
Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"
NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...
A new shot prevents HIV—and breathes new life into a stagnant biotech
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...
Long-lasting HIV prevention shot heads toward approval
A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.
Stocktwits on MSN8d
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance
Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...
Los Angeles Times6y
Taxpayers funded this HIV research. The government patented it. Now a company profits
preventing HIV infection. But the U.S. government, which patented the treatment in 2015, is not receiving a penny for that use of the drug from Gilead Sciences Inc., Truvada’s maker, which ...
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...
2 Reasons to Like GILD (and 1 Not So Much)
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...
Los Angeles Times9y
A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner
More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. Clinical trials ...
Nasdaq8y
Could Gilead Sciences' Game-Changing HIV Pill Solve Its Growth Problem?
Thankfully, with Truvada PrEP opening up a new world of HIV sales, that risk is rapidly disappearing behind us. 10 stocks we like better than Gilead Sciences When investing geniuses David and Tom ...